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Abstract
Background:  Streptococcus agalactiae (group B Streptococcus; GBS) is a significant bacterial
pathogen of neonates and an emerging pathogen of adults. Though transcriptional regulators are
abundantly encoded on the GBS genome, their role in GBS pathogenesis is poorly understood. The
mtaR  gene encodes a putative LysR-type transcriptional regulator that is critical for the full
virulence of GBS. Previous studies have shown that an mtaR- mutant transports methionine at
reduced rates and grows poorly in normal human plasma not supplemented with methionine. The
decreased virulence of the mtaR mutant was correlated with a methionine transport defect;
however, no MtaR-regulated genes were identified.
Results: Microarray analysis of wild-type GBS and an mtaR mutant revealed differential expression
of 12 genes, including 1 upregulated and 11 downregulated genes in the mtaR mutant. Among the
downregulated genes, we identified a cluster of cotranscribed genes encoding a putative
methionine transporter (metQ1NP) and peptidase (pdsM). The expression of four genes potentially
involved in arginine transport (artPQ) and arginine biosynthesis (argGH) was downregulated and
these genes localized to two transcriptional units. The virulence factor cspA, which encodes an
extracellular protease, was downregulated. Additionally, the SAN_1255 locus, which putatively
encodes a protein displaying similarity to plasminogen activators, was downregulated.
Conclusion: To our knowledge, this is the first study to describe the global influence of MtaR on
GBS gene expression. This study implicates the metQ1NP genes as encoding the MtaR-regulated
methionine transporter, which may provide a mechanistic explanation for the methionine-
dependent growth defect of the mtaR mutant. In addition to modulating the expression of genes
involved in metabolism and amino acid transport, inactivation of mtaR affected the expression of
other GBS genes implicated in pathogenesis. These findings suggest the possibility that MtaR may
play a multifaceted role in GBS pathogenesis by regulating the expression of numerous genes.
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Background
Streptococcus agalactiae (group B Streptococcus; GBS) is a
Gram-positive bacterial pathogen of humans. GBS is best
known as a pathogen of neonates, in which it is a leading
cause of pneumonia, sepsis, and meningitis. In recent
years, GBS has also emerged as a significant pathogen of
the immunocompromised, elderly, and adults with
underlying medical conditions [1].
GBS infections progress rapidly, in part due to the vigor-
ous growth of the organism in vivo. Classical virulence fac-
tors such as toxins have been the predominant focus of
most virulence studies; however, recent studies reflect
increasing interest in the connection between bacterial
growth, metabolism, and virulence [2-5]. The metabolic
processes of bacteria used during in vivo growth or survival
are prerequisites for virulence that have often been over-
looked in pathogenesis studies [5], with the notable
exception of iron utilization. Similar to iron, other nutri-
ents may be scarce in vivo and may require significant met-
abolic adaptation for in vivo survival. Because the host
environment is dynamic and ill-defined in terms of avail-
able nutrients, the metabolic processes of pathogenic bac-
teria that are critical for in vivo survival are not easily
predictable without experimentation. Exploration of this
understudied facet of bacterial pathogenesis may lead to
novel therapies directed against bacterial metabolism [2].
Interestingly, most currently-available antibiotics target
essential fundamental bacterial processes including
metabolism.
In neonatal infections, GBS has the striking ability to rap-
idly transition through a diverse range of host environ-
ments and exhibits vigorous growth in many of these
settings, despite its very limited biosynthetic capacities
[6]. In early-onset neonatal disease, GBS first colonizes
the maternal vagina, ascends the birth canal, penetrates
the placental membranes, and proliferates rapidly within
the amniotic fluid. The fetus may aspirate the infected
amniotic fluid during parturition, which can lead to neo-
natal pneumonia. GBS can then penetrate and damage
cellular barriers, transcytose through cells, and enter the
bloodstream. From the bloodstream, the bacterium can
disseminate to multiple organs and penetrate the blood-
brain barrier, leading to meningitis [7].
The mechanisms underlying the ability of GBS to thrive in
diverse host environments are largely uncharacterized.
However, the numerous regulatory proteins encoded
within the GBS genome may reflect the adaptability of the
bacterium. The spectrum of genes controlled by GBS tran-
scription factors will undoubtedly provide insight into
how GBS adapts to the human host. However, compared
with other pathogens such as Streptococcus pyogenes, only a
few global transcriptional profiling studies have been con-
ducted to examine the function of regulatory proteins in
GBS [8-10].
The GBS mtaR gene displays homology to LysR-type tran-
scription regulators (LTTR) and is required for GBS viru-
lence in a neonatal rat model of sepsis [11]. An insertional
inactivation of mtaR  resulted in a mutant displaying
approximately a 1000-fold increase in LD50. Furthermore,
coinfection experiments have shown that the mtaR
mutant survives very poorly in vivo, as compared with the
wild-type strain [11].
During the course of an infection, GBS often invades the
bloodstream and induces a dangerous systemic inflam-
matory response that can lead to fatal sepsis. Experiments
using human plasma (as an ex-vivo model for the nutri-
tional conditions present in the bloodstream) revealed
that inactivation of mtaR causes a methionine-dependent
growth defect in GBS. Furthermore, it was also shown that
the mtaR mutant transported methionine poorly. Thus, it
was hypothesized that MtaR controls a gene or gene(s)
involved in methionine transport and/or metabolism
[11]. However, no direct experimental evidence support-
ing this hypothesis has been reported. Interestingly,
methionine is one of the least abundant amino acids in
normal human blood; thus, methionine scavenging may
be a critical determinant for the survival of GBS as well as
other fastidious pathogens in vivo.
In this study, we performed transcriptional profiling anal-
yses to identify MtaR-regulated genes involved in methio-
nine transport, methionine metabolism, and other
processes related to GBS virulence. The findings of our
study implicate a single gene cluster as encoding the
MtaR-controlled methionine transport system. No other
genes predicted to be involved in methionine metabolism
or transport were found to be affected by the mtaR muta-
tion. Expression of genes implicated in a variety of other
processes including systemic virulence, interaction with
fibrinogen, metabolism, and transport of other amino
acids were affected by the mutation of mtaR. Our findings
reveal that MtaR influences expression of a range of GBS
genes and suggest that MtaR may play a multifactorial role
in GBS virulence.
Results
Establishment of bacterial growth conditions and 
microarray analysis
The GBS strain COH1 [12], a clinical isolate from a case of
fatal infant septicaemia belonging to the hypervirulent ST-
17 lineage [13] was the reference strain for this study. An
isogenic GBS mtaR mutant (DS101) bearing a kanamycin-
resistance cassette insertion was derived by precise allelic
exchange and was utilized as the test strain. The DS101
strain was previously shown to exhibit a methionineBMC Genomics 2008, 9:607 http://www.biomedcentral.com/1471-2164/9/607
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transport defect when grown in chemically defined
medium (CDM) at high methionine concentrations [11].
Mutation of GBS mtaR significantly attenuated growth at
low methionine levels (4 μg/ml), while the wild-type
strain grows normally in the presence of 4 μg/ml methio-
nine (Fig. 1). As nutritional starvation can induce mRNA
degradation and growth rate can modulate gene expres-
sion, we cultured the wild-type and mtaR mutant strains
under conditions in which the strains exhibited identical
growth kinetics (in media containing 400 μg/ml methio-
nine) (Fig. 1).
In preparation for microarray experiments, three cultures
each of COH1 (wild type) and DS101 (mtaR::kan) were
grown to an OD600 of 0.3 in CDM containing 400 μg/ml
methionine. RNA was harvested and processed for hybrid-
ization to microarrays as described above in Materials and
Methods. A custom oligonucleotide microarray (Affyme-
trix, Santa Clara, CA) based on the GBS COH1 genomic
sequence [14] was utilized for microarray analysis. The
entire procedure was repeated three times, giving three
biological replicates for each strain.
Genes were considered differentially expressed if the fol-
lowing three criteria were met: 1) There was a two-fold or
greater difference in signal intensity for the probe set cor-
responding to the gene, 2) statistical analysis (see Materi-
als and Methods and Additional File 1) yielded a P value
less than 0.001, and 3) real-time PCR (qPCR) validated
that the gene was differentially regulated. Genes were
divided into functional categories using a combination of
published experimental evidence and homology searches,
Growth of GBS strains COH1, DS101 (mtaR-), and DS105 (mtaR+/-) in chemically defined medium (CDM) Figure 1
Growth of GBS strains COH1, DS101 (mtaR-), and DS105 (mtaR+/-) in chemically defined medium (CDM). GBS 
strains were cultured statically at 37°C in CDM with either 4 μg/ml or 400 μg/ml methionine. Samples were withdrawn every 
thirty minutes and optical density was measured at 600 nm (O.D.600). Cells were collected at O.D.600 = 0.3 for harvest of RNA.
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and the twelve genes meeting the above criteria are pre-
sented in Table 1. Upon review of the list of differentially-
expressed genes, each gene that was identified as differen-
tially regulated according to the above criteria was found
to have been assigned "Present" calls by the Affymetrix
GCOS software for both strains in all three replicate exper-
iments. The microarray results correlated strongly with the
qPCR results (Table 2), indicating the validity of our data.
Complementation analysis
The mtaR mutant bears a kanamycin cassette insertion in
the 5' region of the mtaR derived by precise allelic replace-
ment of the wild-type mtaR allele [11]. The genes flanking
mtaR on both sides are transcribed in the opposite direc-
tion [11], indicating the mutation is not polar. Previous
complementation analysis, performed by introducing the
wild-type mtaR allele into the mutant in trans [11], con-
firmed that the mtaR mutation was not polar and was
responsible for the attenuation of virulence and the
methionine-dependent growth defect observed in plasma.
Introduction of the wild-type mtaR  allele in trans  also
restored the growth of the mtaR mutant in 4 μg/ml CDM
(Fig. 1), indicating that the mtaR  mutation was also
responsible for the methionine-dependent growth defect
in CDM.
Complementation analysis was performed on six repre-
sentative genes to confirm that the differential regulation
resulted from the engineered mtaR mutation and not from
an unlikely spurious secondary mutation. We measured
gene expression by qPCR in the mtaR mutant (DS101)
and the mtaR mutant in which the wild-type mtaR allele
has been introduced in trans (DS105). For each strain, the
results are expressed as a ratio of gene expression of the
test strain to that of the wild-type strain: metQ1, 0.16
(DS101/COH1), 0.99 (DS105/COH1); cspA, 0.30
(DS101/COH1), 0.98 (DS105/COH1); artP, 0.27
(DS101/COH1), 1.23 (DS105/COH1); artQ, 0.63
(DS101/COH1), 1.07 (DS105/COH1); SAN_1255, 0.5
(DS101/COH1), 0.93 (DS105/COH1). A gene, metQ2,
that was not differentially expressed in the mutant served
as a control, and its expression level (in relation to the
wild-type strain) was not increased when the wild-type
mtaR allele was introduced to the mtaR mutant: metQ2,
1.15 (DS101/COH1), 1.02 (DS105/COH1). These data
indicate that in DS105 (DS101 with the wild-type mtaR
allele in trans), expression of the differentially-expressed
genes was restored to approximately wild-type levels.
Taken together, the complementation results strongly sug-
gest that the mtaR mutation was responsible for the differ-
ential gene regulation observed in this study.
Methionine transport genes
The expression of a gene cluster (metQ1NP) (Fig. 2A) that
displayed strong similarity to established methionine
transport gene clusters in other Gram-positive bacteria
was downregulated in the mtaR mutant. RT-PCR analysis
revealed that the gene cluster was cotranscribed (Fig. 2B).
This cluster is predicted to encode products that are highly
similar to components of bacterial ABC transporters. The
Table 1: S. agalactiae genes that are differentially regulated in the mtaR mutant.
Locus (gene) Function/annotation/homology P value Fold change
Transport and binding proteins
SAN_1753 (metP) ABC transporter, permease 4.4 × 10-6 -2.43
SAN_1754 (metN) ABC transporter, ATP-binding 5.8 × 10-7 -2.43
SAN_1756 (metQ) ABC transporter, substrate-binding 3.5 × 10-11 -5.30
SAN_0595 (artP) ABC transporter, permease 2.5 × 10-7 -2.35
SAN_0596 (artQ) ABC transporter, ATP-binding 9.7 × 10-6 -2.44
Protein fate: degradation of proteins, peptides, and glycopeptides
SAN_1755 (pdsM) Peptidase, M20/M25/M40 family 2.1 × 10-9 -3.72
SAN_2186 (cspA) Serine protease 2.3 × 10-7 -3.20
SAN_1255 Streptokinase-like 1.4 × 10-5 -2.65
Amino acid biosynthesis
SAN_0156 (argG) Argininosuccinate synthase 8.6 × 10-5 -2.60
SAN_0157 (argH) Argininosuccinate lyase 8.7 × 10-6 -2.91
Energy metabolism
SAN_0597 (manB) Phosphomannomutase or Phosphoglucomutase 4.1 × 10-5 -2.04
Hypothetical conserved
SAN_0933 8.3 × 10-4 +2.47
The differentially-regulated genes are grouped into functional categories, based on experimental evidence, protein database searches, and genome 
annotation. Each GBS COH1 gene [14] is indicated by its Comprehensive Microbial Resources locus number (SAN number) available on the J. Craig 
Venter Institute website http://www.jcvi.org/cms/research/projects/cmr/ and gene symbol, when applicable. Fold changes in gene expression (mtaR 
mutant relative to wild-type) and Bayesian P values were derived using Cyber-T [38] analysis of data from three independent biological replicates. 
Criteria for inclusion in this table were the following: Bayesian P value < 0.001, greater than two-fold change, and confirmation of differential 
expression by qPCR (Table 2).BMC Genomics 2008, 9:607 http://www.biomedcentral.com/1471-2164/9/607
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first component of typical bacterial ABC transporters con-
sists of an ATP-binding cassette (ABC), which binds and
hydrolyzes ATP. The second component is a permease,
which forms a channel in the membrane. The third com-
ponent, a substrate-binding protein, imparts specificity to
the system. We identified genes predicted to encode the
ABC component (MetN), the permease component
(MetP), and the substrate-binding component (MetQ1)
in the cluster and found that these genes were downregu-
lated in the mtaR mutant. A gene in this cluster (pdsM) is
predicted to encode a peptidase from the M20/M25/M40
family; the cotranscription of this gene in the metQ1 clus-
ter may suggest the encoded protein is involved in the
breakdown of peptides for nutritional purposes.
In a previous bioinformatics study, a putative gene
(metQ2) located elsewhere on the chromosome was pred-
icated to encode a methionine substrate-binding protein;
this gene was hypothesized to be regulated by MtaR
[15,16]. In our study, microarray analysis indicated that
the metQ2 gene is expressed (data not shown). However,
qPCR analysis revealed no statistically-significant differ-
ence in metQ2 expression between the mtaR mutant and
the wild-type strain (Fig. 3).
Genes involved in arginine and carbohydrate metabolism
A putative operon (artPQmanB) that is predicted to
encode components of another ABC transport system and
a potential phosphomannomutase/phosphoglucomutase
was also downregulated in the mtaR  mutant. The GBS
artPQ genes exhibit strongest similarity to arginine and
glutamine transporters. The artPQ  gene products are
unlikely to be involved in glutamine transport since the
GBS glutamine transporter has been identified [17]. The
manB gene, located adjacent to artQ (Fig. 2A), is predicted
to encode a protein with similarity to phosphomanno-
mutases and phosphoglucomutases. The artPQ and manB
genes were shown to be cotranscribed via RT-PCR analysis
(Fig. 2B).
Two additional genes potentially involved in arginine
metabolism, argG and argH, were downregulated in the
mtaR mutant. SAN_0156 (argG) is predicted to encode
argininosuccinate synthase. The predicted product of
SAN_0157 (argH) displayed homology to argininosucci-
nate lyase, which catalyzes the formation of arginine from
argininosuccinate. In other bacteria, ArgG and ArgH cata-
lyze the two terminal reactions in the biosynthesis of
arginine. The argG and argH genes are clustered (Fig. 2A)
and the results of our RT-PCR analysis (Fig. 2B) indicate
these genes are cotranscribed.
Genes encoding products involved in the GBS-fibrinogen 
interaction
Two genes (cspA and fbsB) that encode products involved
in the interaction between GBS and fibrinogen were dif-
ferentially expressed in the mtaR mutant. Expression of
the virulence-associated cspA gene [18], which encodes a
member of the surface-localized, extracellular cell-enve-
lope proteases (CEPs) [19], was downregulated. The cspA
gene is necessary for virulence and cleavage of fibrinogen
by GBS [18]. Heterologously-expressed CspA has been
shown to cleave fibrinogen [20]. In addition, the expres-
sion of fsbB (SAN_0932), which encodes a fibrinogen-
binding protein, was upregulated by approximately 1.82
fold by microarray analysis (P = .0035; PPDE [<P] = 0.92).
While slightly below the criteria for inclusion in Table 1,
qPCR confirmed that fbsB was upregulated by 1.75 fold in
the mtaR mutant. Moreover, a gene of unknown function
that is adjacent to fbsB (SAN_0933) was upregulated by
~2.5-fold (Table 1) in the mtaR mutant. The results of our
RT-PCR analysis (Fig. 2B) indicate that fbsB  and
Table 2: Validation of differential gene expression observed in microarray experiments via qPCR.
Gene mRNA level change Sense primer sequence (5'-3') Antisense primer sequence (5'-3')
qRT-PCR microarray
SAN_1753 -2.1 -2.4 GGGTTGGGAAGGTGCTTAC TAAACCTCCAATAAGGAACGAC
SAN_1754 -3.0 -2.4 ATGGAATTGTCGGTTATTCAGGAG GTCAGTGTCACCTTGTTGTCG
SAN_1756 -6.5 -5.3 GCTCCAATTCGTATCTATTCTG ATTTGATTAAACCTGCTGACTG
SAN_0595 -3.7 -2.4 AAGATAGTGCTCTCCTTCAAAC CCCTTTCCCAAGATATTTCTCC
SAN_0596 -1.6 -2.4 GCAGGGATTATTGTTGAGC GAAGTCTCTTGTGCGGATTTC
SAN_1755 -6.0 -3.7 GCAGATGAGGTAGAACAGTGG GTGCGGTAATGTGACCTTTATC
SAN_2186 -3.7 -3.2 AATATAAGTTAGGTGCCGTATCTG CGTGTTGTTAGTAGGTGTCTC
SAN_1255 -3.2 -2.7 AAACCCAAATCCTCACATTATTG TCCCATCTTTACATTGACTTCG
SAN_0156 -1.7 -2.6 ATATAAAGGTTCTGCCAAAGTC TGTATAAGTTGCTAAGTTCTCATC
SAN_0157 -2.8 -2.9 TTGGACATCATCTAATGGCTTAC ATATGGCGGTCAATAGGAAATG
SAN_0597 -2.1 -2.0 GGCGGGATTGAGAGGTAAAC TAACGGACATCATAACTAACTGC
SAN_0933 +1.7 +2.5 CAGAAATAAGGCATCAACTACC AAAGAATAGGCATTATCAATACGBMC Genomics 2008, 9:607 http://www.biomedcentral.com/1471-2164/9/607
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Gene clusters under the control of MtaR Figure 2
Gene clusters under the control of MtaR. (A) Genes differentially expressed in the mtaR mutant that cluster in four 
regions of the GBS COH1 chromosome. The filled, colored arrows represent genes differentially expressed in the mtaR 
mutant. The color of the arrow corresponds to the functional category predicted or established for the each gene: light green, 
transport and binding; light pink, protein fate; dark green, energy metabolism; grey, hypothetical, and dark pink, amino acid bio-
synthesis. Open arrows represent genes not differentially expressed in the mtaR mutant. The arrows above the gene clusters 
represent primers used for transcriptional linkage experiments depicted in panel B. (B) RT-PCR was performed using RNA 
harvested from GBS strain COH1. PCR reactions were performed with or without RT enzyme or chromosomal DNA. The 
number of the cluster analyzed in each experiment is indicated above the corresponding gel. The designation and location of 
the primers utilized are indicated in panel A and the primer sequences are listed in the text.
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SAN_0933 are cotranscribed. Taken together, these find-
ings indicate that fbsB expression is under the control of
MtaR.
Discussion
Our findings strongly suggest that the metQ1NP  genes
encode the MtaR-regulated methionine transport system.
Additionally, we found that the expression of four genes
potentially related to arginine metabolism (artPQ  and
argGH) were under the influence of MtaR. Furthermore, a
gene (manB) possibly involved in carbohydrate metabo-
lism was found to be controlled by MtaR. Of note, carbo-
hydrate metabolism has recently been linked to the
pathogenesis of a number of streptococci [3,21]. In addi-
tion to modulating expression of genes involved in trans-
port and metabolic processes, our study also indicates
MtaR influences the expression of genes (fbsB and cspA)
involved in other aspects of GBS pathogenesis. Overall, 12
genes met the criteria for being differentially regulated.
Given the level of replication (3 biological replicates per
strain), there remains the possibility of false negatives; it
is possible that some genes in the MtaR-dependent regu-
lon, including those with less than a two-fold change in
expression, have not been revealed in this study.
Methionine transport
The metQ1NP gene cluster was the only putative methio-
nine transport system affected by the mtaR  mutation.
Inactivation of metQ1NP homologs in Bacillus subtilis [22]
and Streptococcus mutans [23] abolished methionine trans-
port. Our preliminary attempts to inactivate the metQ1
gene (via plasmid insertion-duplication mutagenesis)
were unsuccessful and appeared to arrest growth of the
organism (J. Bryan and D. Shelver, unpublished results),
qPCR evaluation of genes encoding putative methionine transport components Figure 3
qPCR evaluation of genes encoding putative methionine transport components. qPCR was used to examine MtaR-
dependent expression of putative methionine ABC transport genes (substrate-binding components). Melting curve analysis and 
agarose electrophoresis of PCR products were performed to ensure that each primer pair only produced a single amplicon. 
The ΔΔCt quantification method was used to determine relative gene expression differences normalized to rpsL (housekeeping 
control) expression. metQ1 expression (open bars) and metQ2 expression (filled bars) were compared between strains. The 
comparisons were performed by calculating the gene expression ratios of DS101 (mtaR-) or DS105 (DS101 complemented 
with a low-copy plasmid bearing the wild-type mtaR+ allele) to those of COH1.
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even when the medium was supplemented with high
(400  μg/ml) concentrations of methionine or peptide
methionine sources. The simplest interpretation of these
results is that the cluster encodes a sole GBS methionine
transporter. However, because the mutation we attempted
to engineer is predicted to be polar onto downstream
genes, it is uncertain which of the components are essen-
tial for growth. Future studies are necessary to test the
hypothesis that metQ1NP encodes the sole GBS methio-
nine transport system.
MtaR controls genes encoding products associated with 
GBS-fibrinogen interaction
In addition to regulating amino acid transport and metab-
olism, MtaR also appears to control the expression of
genes involved in the interaction between GBS and fibrin-
ogen. Fibrinogen is a host protein that plays a key role in
many facets of bacterial pathogenesis and is a mediator of
the host defense against pathogens [24,25]. However,
pathogenic bacteria can subvert fibrinogen and the associ-
ated coagulation cascade for their own purposes [25]. For
example, fibrinogen can be used by pathogenic bacteria
for adherence [26] and evasion of the innate immune sys-
tem [27].
Expression of least two genes involved or implicated in
the interaction between GBS and fibrinogen were differ-
entially expressed in the mtaR mutant. In particular, the
expression of fbsB was upregulated. In addition to binding
fibrinogen, the encoded product (FbsB) promotes GBS
invasion of epithelial cells [28]. Additionally, the cspA
gene, which encodes a serine protease from the cell-enve-
lope family of proteases (CEPs) [19], was downregulated
in the mtaR mutant. All reports of CEPs in pathogenic
streptococci indicate that these proteins play roles in viru-
lence [18,19,29,30]. CspA has the ability to promote
cleavage of the Aα subunit of fibrinogen at a single site
[18]. However, it cleaves very few other substrates (see
paragraph below), indicating a high level of specificity.
The cspA gene is not necessary for GBS growth in plasma
or laboratory broth (THB, CDM) and COH1 cells do not
cleave the general protease substrate casein regardless of
the presence or absence of a functional cspA gene [18], (T.
O. Harris and C. E. Rubens, personal communication).
Thus, similar to the CEPs of other pathogenic streptococci,
the GBS CspA protein does not appear to play a nutri-
tional role [18].
The cspA gene is required for the full virulence of GBS in a
rat model of neonatal sepsis [18] but the connection
between the fibrinogen-cleaving activity of CspA and GBS
virulence is not yet clear. However, previous studies have
shown that CspA contributes to neutrophil evasion by
promoting resistance to opsonophagocytic killing [18].
Furthermore, CspA proteolyzes certain members of the
CXC class of chemokines, abolishing their ability to
attract neutrophils (J. Bryan and D. Shelver, unpublished
data). Thus, in addition to promoting GBS survival in vivo
by regulating the metQ1NP cluster, MtaR may contribute
to GBS virulence by upregulating the expression of CspA.
Numerous recent studies have focused on a Streptococcus
pyogenes CEP (SpyCEP/ScpC) that is also capable of prote-
olyzing CXC chemokines [30-33]. This protease has been
implicated in necrotizing fasciitis and contributes to the
virulence of S. pyogenes in an animal model of spreading
necrosis. Similar to CspA of GBS, S. pyogenes SpyCEP/ScpC
is thought to be a virulence factor that allows S. pyogenes
to evade neutrophils. However, regulation of spyCEP by
an MtaR homolog has not been reported.
Our results revealed that a gene of unknown function
(SAN_1255), whose product shares similarity with the
plasminogen activators of a variety of bacteria (i. e., 20%
identity and 35% similarity to Streptococcus uberis PauB
[34]), was found to be downregulated. Plasminogen is the
inactive form of a human protease that, when converted
to a highly active protease (plasmin), cleaves fibrin (the
polymerized form of fibrinogen found in clots) as well as
a number of other host proteins. Bacterial plasminogen
activators are potent virulence factors that promote inva-
sive infections and bacterial spread [24]. However, it has
not been determined if GBS can activate plasminogen in
the absence of host factors [35]; thus, the function of
SAN_1255 remains unclear. Due to the observation that
SAN_1255 exhibits considerable strain-to-strain allelic
variability, it has been speculated that its product may
interact with the host [36].
The MET box and MtaR-dependent regulation of gene 
expression
In a previous bioinformatics study, Rodionov et al.
observed that a region of two-fold rotational symmetry
(the MET box) precedes two GBS genes (metQ1  and
metQ2) predicted to encode products similar to bacterial
methionine transport components and a gene (metE)
whose predicted product shows homology with enzymes
that catalyze the conversion of homocysteine to methio-
nine [15]. The MET box is characterized by the TATAGTT-
TnAAACTATA consensus sequence [16], and strongly
resembles a LysR-type transcriptional regulatory protein
binding site.
During the course of our studies, a report was published
describing an apparent S. mutans MtaR ortholog, MetR,
that is 80% identical to MtaR [23]. This study identified
MET boxes upstream of several genes encoding compo-
nents of the methionine biosynthetic pathway as well as a
cluster encoding a methionine transporter [23]. In electro-
phoretic mobility shift assays, purified S. mutans MetRBMC Genomics 2008, 9:607 http://www.biomedcentral.com/1471-2164/9/607
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bound to DNA fragments containing MET boxes; how-
ever, DNA footprinting was not performed to specifically
locate the MetR binding site. The authors speculated that
streptococcal MtaR/MetR homologs act specifically as reg-
ulators of methionine metabolism and activate gene
expression in response to methionine starvation. How-
ever, this study did not globally examine genes influenced
by MetR (i.e., genes not preceded by MET boxes). Some
genes preceded by MET boxes were not subject to regula-
tion by MetR and methionine starvation. Also, MetR
bound to some DNA fragments containing MET boxes but
did not affect regulation of these genes. The correlation
between MET boxes and MetR regulation was thus incom-
plete. It is therefore not clear if MET boxes are the sole
determinants of MetR-dependent regulation.
In our study, despite the presence of MET boxes preceding
three genes potentially related to methionine transport
and metabolism (metQ1, metQ2, and metE), only expres-
sion of the metQ1NP transport cluster was affected by the
mtaR mutation. Furthermore, computerized searches of
DNA regions in the vicinity of other MtaR-regulated genes
did not reveal MET boxes. These results can be explained
if MtaR has the ability to regulate genes by binding to
sequences other than MET boxes or if MtaR influences
expression of the differentially-regulated genes indirectly
via other regulatory proteins. Localization of MtaR bind-
ing sites by DNAse footprinting or other techniques has
not yet been possible since MtaR, like a number of other
LTTRs, has been recalcitrant to expression in an active
form. However, efforts to purify MtaR and definitively
identify its binding site are ongoing. Regardless of
whether MtaR influences expression of genes in a direct or
indirect manner, our findings provide insight into the
ability of MtaR to regulate genes involved in a variety of
processes in GBS.
Conclusion
To our knowledge, this is the first study to describe the
spectrum of genes controlled by MtaR. Our findings indi-
cate that MtaR activates expression of a specific methio-
nine transport gene cluster (metQ1NP), which may allow
the organism to efficiently scavenge methionine in vivo.
Genes potentially involved in other aspects of metabolism
(e.g., arginine transport and sugar metabolism) were also
identified as influenced by MtaR. In addition, our findings
reveal that MtaR controls the expression of two previ-
ously-characterized genes (fbsB and cspA) that have been
implicated in other facets of GBS pathogenesis.
Methods
Materials (chemicals, media, and molecular biology 
reagents)
Media for the routine growth of Escherichia coli (LB broth)
and  Streptococcus agalactiae (Todd-Hewitt Broth; THB)
were purchased from Becton, Dickinson and Company
(Sparks, MD). Chemically-defined media (CDM) was pre-
pared as described by Willett and Morse [37] with the
exception that methionine was added to the final concen-
trations indicated. Chemical reagents were purchased
from Sigma-Aldrich (St. Louis, MO) unless otherwise
noted.
Strains and plasmids
Streptococcus agalactiae strain COH1 is a minimally-pas-
saged clinical isolate obtained from a fatal case of human
infant septicaemia [12] and belongs to hypervirulent ST-
17 lineage [13]. The DS101 strain (mtaR-) is an isogenic
derivative of COH1 that harbors a kanamycin-resistance
cassette insertion in mtaR [11]. Plasmid pDS8, utilized for
complementation of DS101 [11], is a low-copy plasmid
bearing mtaR. The DS105 strain is an isogenic derivative of
DS101 that harbors pDS8 [11].
DNA microarray design
A custom DNA oligonucleotide microarray (LSUHSC-
S_Shelver_GBS_5K_V1.0) was designed by Affymetrix
(Santa Clara, CA) and manufactured by Nimblegen (Mad-
ison, WI) for use on the Affymetrix GeneChip® platform.
The NimbleExpress™ 49 format with a 17 micron feature
size was utilized. Oligonucleotides (25-mers) were
selected according to the genomic sequence of GBS strain
COH1 [14]. Each potential coding region was represented
by 24 perfectly matched (PM) and 24 mismatched (MM)
oligonucleotides when possible. The oligonucleotide sets
were tiled twice on each chip. The microarray design has
been deposited in the Gene Expression Omnibus (GEO)
http://www.ncbi.nlm.nih.gov/geo/ under accession
number GPL7515.
RNA isolation
In preparation for by real-time PCR analysis (qPCR), GBS
strains were cultured at 37°C in CDM to an O.D.600 of 0.3
and 50 ml of cells were harvested by centrifugation. The
GBS cells were then placed in a 950 μl suspension con-
taining QBio lysing matrix B, 50 mM sodium acetate pH
4.0, 0.5% SDS, and 25% acidic phenol (Amresco; Solon,
OH). Cells were mechanically disrupted with the lysing
matrix using a FastPrep® 120 device (MP Biomedicals;
Solon, OH) with a speed setting of 5 and a pulse length of
22 seconds. The mixture was separated by centrifugation
for 10 minutes. The aqueous phase of the suspension was
extracted twice with equal volumes of acidic phenol/chlo-
roform (Amresco), followed by an equal volume of chlo-
roform. RNA was then precipitated by adding two
volumes of 100% ethanol and sodium acetate pH 5.2 to a
final concentration 0.3 M. Samples were incubating at -
20°C for 1 hour, pelleted in a refrigerated centrifuge,
dried, and resuspended in diethylpyrocarbonate (DEPC)-
treated water. Residual DNA was then removed via treat-BMC Genomics 2008, 9:607 http://www.biomedcentral.com/1471-2164/9/607
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ment with RNase-free DNaseI (Promega; Madison, WI)
and purification with an RNeasy (Qiagen; Valencia, CA)
column according to the manufacturer's instructions.
RNA was stored at -80°C.
In preparation for microarray analysis, the protocol
described above was modified as follows. After cell dis-
ruption and recovery of the aqueous phase, RNA was pre-
cipitated via the addition of two volumes of 100%
ethanol and sodium acetate (pH 5.2) to a final concentra-
tion of 0.3 M. TRIzol reagent (1 ml; Sigma-Aldrich) was
then added and the mixture was incubated at room tem-
perature for 5 minutes Chloroform (200 μl) was added,
shaken vigorously, and allowed to remain at room tem-
perature for 2 minutes. The mixture was then centrifuged
for 10 minutes, the aqueous phase was recovered and
RNA was precipitated with an equal volume of 100% iso-
propanol. The pellet was air-dried and resuspended in 50
μl of DEPC-treated water. Residual DNA was removed as
described above.
Real-time PCR (qPCR) analysis
Appropriate primers were designed using the Beacon
Design program (Premier Biosoft International, Palo Alto,
CA). The purified RNA was then used as template in the
Superscript III first strand synthesis kit (Invitrogen;
Carlsbad, CA). The resulting cDNA was then used as tem-
plate in a PCR reaction with SYBR Green and iTaq (Bio-
Rad; Hercules, CA). Fluorescence of the SYBR Green was
measured using a Bio-Rad iCycler thermocycler. Melting
curve analyses and electrophoresis of PCR products on
agarose gels were performed to ensure that each primer
pair only produced a single amplicon. The ΔΔCT method
was used to estimate fold changes in gene expression
between the COH1 and DS101 strains using rpsL  (a
housekeeping gene) as a reference. To ensure the ΔΔCT
method was valid for estimating relative transcript levels,
primer validation was performed to demonstrate that the
efficiencies of target and reference were approximately
equal and that the absolute values of the slopes of log
input RNA amount versus ΔCT were < 0.1.
Microarray analysis
The integrity of the purified RNA was assessed using an
Agilent 2100 Bioanalyzer and a RNA 6000 Nano LabChip
Kit (Agilent; Palo Alto, CA). GeneChip targets were pre-
pared according to the manufacturer's protocols (Prokary-
otic Expression Manual, Affymetrix). The cDNA samples
were synthesized from 10 μg of total RNA using Super-
script II reverse transcriptase (Invitrogen). Carryover RNA
was degraded using 1 N NaOH followed by treatment
with 1 N HCl. The cDNA samples were purified and con-
centrated using a MinElute™ PCR Purification kit (Qia-
gen). Samples were fragmented using DNase I (Promega;
Madison, WI) and biotin end-labeled using the GeneChip
DNA Labeling Reagent (Affymetrix). A hybridization
cocktail containing 3.9 μg labeled cDNA was hybridized
to the arrays. Hybridization was performed for 16 hours
with a rotation of 60 rpm at a temperature of 45°C in a
GeneChip Hybridization Oven 640 (Affymetrix). Arrays
were washed and stained with a streptavidin-phycoeryth-
rin conjugate using predefined protocols with a GeneChip
Fluidics Station 450 (protocol ProkGE-WS2_450). Arrays
were scanned with a GeneChip Scanner 300 7G (Affyme-
trix). Scanned microarray images were analyzed using
GeneChip Operating Software 1.4 (Affymetrix). Arrays
were globally scaled to a target intensity value of 500 to
compare individual experiments. The microarray data has
been deposited in the Gene Expression Omnibus (GEO)
http://www.ncbi.nlm.nih.gov/geo/ under accession
number GSE13325.
Genes were assessed for differential expression using
Cyber-T [38] version 8.01 http://cybert.microar
ray.ics.uci.edu/ with the following settings: the Bayesian
prior estimate was 10, the sliding window size was 101,
and the β-fit iteration value was 2. We defined the cutoff
value for differential gene expression as transcripts that
showed a >2.0-fold change and a Bayesian t-test P value of
< 0.001. The posterior probability of differential expres-
sion (PPDE) (< p) value for the genes identified was >
0.964. The results of the Cyber-T analysis for all genes are
included as Additional file 1.
RT-PCR transcriptional mapping
RT-PCR was used to test if differentially-regulated genes
present in clusters (Fig. 2) were cotranscribed. RNA was
isolated as described above for qPCR analysis. Reverse
transcription was accomplished by combining 2 pmol of
sequence-specific primers,
5'TAAACCTCCAATAAGGAACGAC3' (SAN1753anti),
5'CAAAGAATAGGCATTATCAATACG3' (SAN0933anti),
5'ATAACGGACATCATAACTAACTGC3' (SAN0597anti),
5'ATATGGCGGTCAATAGGAAATG3' (SAN0157anti)
with 250 ng of RNA and dNTPs were added to a final con-
centration of 1 mM. The resulting mixture was heated to
70°C for 5 minutes and placed immediately on ice. RNa-
sin (Promega), DTT, and M-MLV reverse transcriptase
were then added. This mixture was incubated for 10 min-
utes at 25°C, 50 minutes at 37°C, and 15 minutes at
70°C. The cDNA was then digested with RNaseH (Invitro-
gen) to remove RNA/DNA hybrids. For the subsequent
PCR reactions, the following primer pairs were used:
SAN1756sense (5'GCTCCAATTCGTATCTATTCTG3') and
SAN1753anti; SAN0595sense (5'AAGATAGTGCTCTCCT
TCAAAC3') and SAN0597anti; SAN0932sense (5'AACAG
TTAATCAGTATGAAGCG3') and SAN0933anti; and
SAN0156sense (5'CTGTCTGTATGGATGTTGGC3') and
SAN0157anti. The primer locations within the clusters are
indicated on Fig. 2A. GBS chromosomal DNA wasBMC Genomics 2008, 9:607 http://www.biomedcentral.com/1471-2164/9/607
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included in control reactions. PCR products were visual-
ized by agarose gel electrophoresis.
Gene identification and similarity (TIGR/BLAST)
Gene identification was performed by BLAST searches
[39], ClustalW alignments [40], and annotation of GBS
and related genomes http://www.jcvi.org/cms/research/
projects/cmr/. Searches for MET boxes or sequences simi-
lar to MET boxes were conducted as described [41].
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